about
CRISPR/Cas9 and cancer targets: future possibilities and present challengesHepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genesMinimizing off-Target Mutagenesis Risks Caused by Programmable NucleasesApplication of CRISPR/Cas9 Technology to HBVProgress and Prospects of Anti-HBV Gene Therapy DevelopmentModeling Viral Infectious Diseases and Development of Antiviral Therapies Using Human Induced Pluripotent Stem Cell-Derived SystemsCurrent and future directions for treating hepatitis B virus infectionEpstein-Barr Virus: Diseases Linked to Infection and TransformationFuture Therapy for Hepatitis B Virus: Role of ImmunomodulatorsNovel therapeutic approaches for hepatitis B virus covalently closed circular DNAMolecular biology of hepatitis B virus infectionHepatitis B virus molecular biology and pathogenesisCRISPR/Cas9-loxP-Mediated Gene Editing as a Novel Site-Specific Genetic Manipulation Tool.CRISPR/Cas9 in allergic and immunologic diseases.CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virusGenome editing and the next generation of antiviral therapy.The CRISPR/Cas9 genome editing methodology as a weapon against human virusesSpinoculation Enhances HBV Infection in NTCP-Reconstituted HepatocytesDoes Tyrosyl DNA Phosphodiesterase-2 Play a Role in Hepatitis B Virus Genome Repair?Reprogrammed CRISPR-Cas9 targeting the conserved regions of HPV6/11 E7 genes inhibits proliferation and induces apoptosis in E7-transformed keratinocytesCRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC InfectionDual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication.Combinatorial RNA Interference Therapy Prevents Selection of Pre-existing HBV Variants in Human Liver Chimeric Mice.Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape.Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeuticDetection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy.Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense.Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus.RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.An Effective Molecular Target Site in Hepatitis B Virus S Gene for Cas9 Cleavage and Mutational InactivationMinicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs.Inhibition of JCPyV infection mediated by targeted viral genome editing using CRISPR/Cas9CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9.CRISPR-Cas9: a new and promising player in gene therapy.Chronic hepatitis B: A wave of new therapies on the horizon.Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.Advances in therapeutics for chronic hepatitis B.CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.CRISPR Editing in Biological and Biomedical Investigation.
P2860
Q26769907-91E86C95-5972-42B2-985C-AC04FAE2248BQ26772317-8092B5BE-8832-4EB9-8838-5BA6F54C8763Q26778992-F90E4244-27FE-4C7B-B878-C478B6F84125Q26779150-8C059EDE-C90C-4C67-8393-C60CA81AC0C4Q26799228-B79CEB3D-B98B-46D7-AFC3-980218721393Q26799933-9AF8DC58-3C28-4844-9BE3-3C9CF9464C30Q26851240-7590B085-5F82-44D3-B3FD-90B0EB5DC5ECQ28074586-4ECE350D-5F42-4728-800C-0F51C27BC091Q28078148-8AA07111-DC9E-4195-975D-7E626123ABF0Q28081274-38D5EB2D-AF98-41C6-998F-912D1554C13AQ28083478-AEA352AB-34D1-485B-8D81-C39EA99A5B55Q28818406-EEB1FD8A-366C-4B42-BAD7-35044DC62D45Q33676110-E287860A-5346-400F-88ED-A9661BDBA8E7Q34047460-28DF3186-A7AA-4B3A-868B-78539DDDA073Q34478938-1CA58440-C74E-4786-902A-5F02BD5ABE2CQ34529971-8BB0E9CA-DF6F-46CC-8ABF-8FEAECA62026Q35654689-1922B7B6-46F2-4360-9A8D-0F7E0238CBBAQ35662475-E564E88D-E4D6-4DFB-A6E7-FFE817731722Q35664939-DA8C7F71-B412-406F-8EF7-60019EB6520AQ35728189-E341D681-BAEC-4E96-8795-A70DFF0F5789Q35770584-2ED68C65-9FD8-4D3E-8853-8E5156D4595DQ35992385-0BC6D5DC-1DA6-41A2-8998-70F4F1D3066BQ36181757-E694D335-6F03-4FBF-8B63-8F9872F6FD00Q36216276-84785EF0-B170-48D6-84BC-22F966A85C96Q36386251-E5083B90-BF2F-434B-BA7D-267733805822Q36494284-09956F59-41ED-42D4-BCFF-7F5D902DF1E4Q36730743-5834BD33-6ED5-43B0-A5D8-458BDB86CE7AQ36951290-02228953-B907-4AC1-8F6D-9DF25C083C7FQ37137877-C2A3A089-896F-48A9-97C7-AD324A44F2E1Q37201993-D030F880-C6F3-45CC-97CB-A705BE9DD2C3Q37397410-DC27B5A7-1967-4F91-924F-0CC25E73F1C4Q37411994-CE13868A-6759-4D98-A86B-D6F3E06B0A8BQ37559174-B0B1C448-0A03-4957-80F9-A4F1DC501104Q37714431-047728DD-AD0E-45AD-A889-B2CF54A9CF4DQ38364993-E8BF9949-10C7-48D5-8CB0-4719AC3D8CD0Q38538107-C37D75D2-6393-4F49-84DA-D4E85EFF91EFQ38566445-77CDA94E-4456-4F79-9EBD-61BFB57ED0AEQ38585657-8DB11EC7-AAE4-437B-85B9-A322EF3FFE6AQ38618922-09D1ECFB-793A-4334-A6DE-10AA0FB784F0Q38645581-1A55DA1A-580B-49EC-822B-BBE6524E9C7C
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Targeting Hepatitis B Virus With CRISPR/Cas9.
@ast
Targeting Hepatitis B Virus With CRISPR/Cas9.
@en
Targeting Hepatitis B Virus With CRISPR/Cas9.
@nl
type
label
Targeting Hepatitis B Virus With CRISPR/Cas9.
@ast
Targeting Hepatitis B Virus With CRISPR/Cas9.
@en
Targeting Hepatitis B Virus With CRISPR/Cas9.
@nl
prefLabel
Targeting Hepatitis B Virus With CRISPR/Cas9.
@ast
Targeting Hepatitis B Virus With CRISPR/Cas9.
@en
Targeting Hepatitis B Virus With CRISPR/Cas9.
@nl
P2860
P356
P1476
Targeting Hepatitis B Virus With CRISPR/Cas9.
@en
P2093
Christoph Seeger
P2860
P356
10.1038/MTNA.2014.68
P577
2014-12-16T00:00:00Z